RU2679308C2 - Активный энантиомер додецил 2-(n,n-диметиламино)-пропионата - Google Patents
Активный энантиомер додецил 2-(n,n-диметиламино)-пропионата Download PDFInfo
- Publication number
- RU2679308C2 RU2679308C2 RU2013119439A RU2013119439A RU2679308C2 RU 2679308 C2 RU2679308 C2 RU 2679308C2 RU 2013119439 A RU2013119439 A RU 2013119439A RU 2013119439 A RU2013119439 A RU 2013119439A RU 2679308 C2 RU2679308 C2 RU 2679308C2
- Authority
- RU
- Russia
- Prior art keywords
- dimethylamino
- propionate
- dodecyl
- ddaip
- lansoprazole
- Prior art date
Links
- HSMMSDWNEJLVRY-INIZCTEOSA-N dodecyl (2s)-2-(dimethylamino)propanoate Chemical compound CCCCCCCCCCCCOC(=O)[C@H](C)N(C)C HSMMSDWNEJLVRY-INIZCTEOSA-N 0.000 title description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003174 lansoprazole Drugs 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000000243 solution Substances 0.000 claims abstract description 9
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 230000001965 increasing effect Effects 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 4
- 239000003186 pharmaceutical solution Substances 0.000 claims abstract 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 2
- 230000035515 penetration Effects 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 11
- -1 accelerators Substances 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005809 transesterification reaction Methods 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- UPGMLKNCPUCDSU-UHFFFAOYSA-N ethyl 2-(dimethylamino)propanoate Chemical compound CCOC(=O)C(C)N(C)C UPGMLKNCPUCDSU-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000006485 reductive methylation reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 210000004906 toe nail Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- TYRGLVWXHJRKMT-QMMMGPOBSA-N n-benzyloxycarbonyl-l-serine-betalactone Chemical compound OC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1 TYRGLVWXHJRKMT-QMMMGPOBSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41899610P | 2010-12-02 | 2010-12-02 | |
| US61/418,996 | 2010-12-02 | ||
| PCT/US2011/062579 WO2012075107A2 (en) | 2010-12-02 | 2011-11-30 | Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013119439A RU2013119439A (ru) | 2015-01-10 |
| RU2679308C2 true RU2679308C2 (ru) | 2019-02-07 |
Family
ID=46172526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013119439A RU2679308C2 (ru) | 2010-12-02 | 2011-11-30 | Активный энантиомер додецил 2-(n,n-диметиламино)-пропионата |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20130267562A1 (enExample) |
| EP (1) | EP2646015B1 (enExample) |
| JP (1) | JP6109075B2 (enExample) |
| KR (1) | KR102004552B1 (enExample) |
| CN (1) | CN103930105B (enExample) |
| AU (2) | AU2011336692B2 (enExample) |
| BR (1) | BR112013012799A8 (enExample) |
| CA (1) | CA2817417C (enExample) |
| CL (1) | CL2013001391A1 (enExample) |
| CR (1) | CR20130324A (enExample) |
| ES (1) | ES2801999T3 (enExample) |
| IL (1) | IL226173A (enExample) |
| MX (1) | MX2013005522A (enExample) |
| NZ (1) | NZ609826A (enExample) |
| PH (1) | PH12013501104A1 (enExample) |
| PL (1) | PL2646015T3 (enExample) |
| RU (1) | RU2679308C2 (enExample) |
| SG (2) | SG10201803321TA (enExample) |
| WO (1) | WO2012075107A2 (enExample) |
| ZA (1) | ZA201304840B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014028780A2 (en) * | 2012-08-15 | 2014-02-20 | Nexmed Holdings, Inc. | Antifungal compounds and methods of use |
| US8900625B2 (en) | 2012-12-15 | 2014-12-02 | Nexmed Holdings, Inc. | Antimicrobial compounds and methods of use |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6118020A (en) * | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
| WO2005051960A2 (en) * | 2003-11-22 | 2005-06-09 | Midwest Research Laboratories, Llc | Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents |
| EA009024B1 (ru) * | 2002-06-25 | 2007-10-26 | АКРУКС ДиДиЭс ПиТиУай ЭлТиДи | Фармацевтическая композиция для чрескожной доставки активного агента (варианты) |
| US20070269379A1 (en) * | 2003-07-23 | 2007-11-22 | Samir Mitragotri | Penetration Enhancer Combinations for Transdermal Delivery |
| RU2358718C2 (ru) * | 2003-03-21 | 2009-06-20 | Нексмед Холдингс, Инк. | Противогрибковое покрытие для ногтей и способ его применения |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323241B1 (en) * | 2000-01-10 | 2001-11-27 | Nexmed (Holdings) Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
| US20050181030A1 (en) * | 2003-01-03 | 2005-08-18 | Mo Y. J. | Topical stabilized prostaglandin E compound dosage forms |
| PL1670433T3 (pl) * | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
| RU2012153177A (ru) * | 2010-05-04 | 2014-06-20 | Нексмед Холдингс, Инк. | Композиции низкомолекулярных терапевтических средств |
| US8900625B2 (en) * | 2012-12-15 | 2014-12-02 | Nexmed Holdings, Inc. | Antimicrobial compounds and methods of use |
-
2011
- 2011-11-30 NZ NZ609826A patent/NZ609826A/en not_active IP Right Cessation
- 2011-11-30 KR KR1020137013227A patent/KR102004552B1/ko not_active Expired - Fee Related
- 2011-11-30 MX MX2013005522A patent/MX2013005522A/es unknown
- 2011-11-30 JP JP2013542128A patent/JP6109075B2/ja not_active Expired - Fee Related
- 2011-11-30 PL PL11845087T patent/PL2646015T3/pl unknown
- 2011-11-30 PH PH1/2013/501104A patent/PH12013501104A1/en unknown
- 2011-11-30 US US13/991,111 patent/US20130267562A1/en not_active Abandoned
- 2011-11-30 EP EP11845087.3A patent/EP2646015B1/en active Active
- 2011-11-30 CA CA2817417A patent/CA2817417C/en not_active Expired - Fee Related
- 2011-11-30 AU AU2011336692A patent/AU2011336692B2/en not_active Ceased
- 2011-11-30 WO PCT/US2011/062579 patent/WO2012075107A2/en not_active Ceased
- 2011-11-30 SG SG10201803321TA patent/SG10201803321TA/en unknown
- 2011-11-30 SG SG2013035258A patent/SG190199A1/en unknown
- 2011-11-30 ES ES11845087T patent/ES2801999T3/es active Active
- 2011-11-30 CN CN201180054224.5A patent/CN103930105B/zh not_active Expired - Fee Related
- 2011-11-30 RU RU2013119439A patent/RU2679308C2/ru not_active Application Discontinuation
- 2011-11-30 BR BR112013012799A patent/BR112013012799A8/pt not_active Application Discontinuation
-
2013
- 2013-05-05 IL IL226173A patent/IL226173A/en active IP Right Grant
- 2013-05-16 CL CL2013001391A patent/CL2013001391A1/es unknown
- 2013-06-26 CR CR20130324A patent/CR20130324A/es unknown
- 2013-06-28 ZA ZA2013/04840A patent/ZA201304840B/en unknown
-
2017
- 2017-01-17 AU AU2017200314A patent/AU2017200314A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6118020A (en) * | 1999-05-19 | 2000-09-12 | Nexmed Holdings, Inc. | Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate |
| EA009024B1 (ru) * | 2002-06-25 | 2007-10-26 | АКРУКС ДиДиЭс ПиТиУай ЭлТиДи | Фармацевтическая композиция для чрескожной доставки активного агента (варианты) |
| RU2358718C2 (ru) * | 2003-03-21 | 2009-06-20 | Нексмед Холдингс, Инк. | Противогрибковое покрытие для ногтей и способ его применения |
| US20070269379A1 (en) * | 2003-07-23 | 2007-11-22 | Samir Mitragotri | Penetration Enhancer Combinations for Transdermal Delivery |
| WO2005051960A2 (en) * | 2003-11-22 | 2005-06-09 | Midwest Research Laboratories, Llc | Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents |
Non-Patent Citations (3)
| Title |
|---|
| Novotny J. et al. Dimethylamino Acid Esters as Biodegradable and Reversible TransdermalPermeation Enhancers: Effects of Linking Chain Length, Chiralityand Polyfluorination. Pharmaceutical Research, Vol. 26, No. 4, April 2009, pp.811-821. * |
| Novotny J. et al. Dimethylamino Acid Esters as Biodegradable and Reversible TransdermalPermeation Enhancers: Effects of Linking Chain Length, Chiralityand Polyfluorination. Pharmaceutical Research, Vol. 26, No. 4, April 2009, pp.811-821. Потапов В.М. Стереохимия. Учеб. пособие для вузов. - 2-е изд., перераб. и доп. - М.: Химия, 1988. - 464 с. * |
| Потапов В.М. Стереохимия. Учеб. пособие для вузов. - 2-е изд., перераб. и доп. - М.: Химия, 1988. - 464 с. * |
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201803321TA (en) | 2018-06-28 |
| ES2801999T3 (es) | 2021-01-15 |
| BR112013012799A8 (pt) | 2018-01-09 |
| CN103930105A (zh) | 2014-07-16 |
| AU2011336692B2 (en) | 2017-02-16 |
| KR20140023875A (ko) | 2014-02-27 |
| AU2017200314A1 (en) | 2017-02-02 |
| MX2013005522A (es) | 2013-07-17 |
| CA2817417C (en) | 2020-12-29 |
| SG190199A1 (en) | 2013-06-28 |
| CL2013001391A1 (es) | 2013-11-08 |
| US20130267562A1 (en) | 2013-10-10 |
| KR102004552B1 (ko) | 2019-10-01 |
| PL2646015T3 (pl) | 2020-11-30 |
| EP2646015A2 (en) | 2013-10-09 |
| CR20130324A (es) | 2013-08-13 |
| BR112013012799A2 (pt) | 2016-09-13 |
| WO2012075107A2 (en) | 2012-06-07 |
| CN103930105B (zh) | 2019-11-01 |
| WO2012075107A3 (en) | 2014-03-06 |
| RU2013119439A (ru) | 2015-01-10 |
| JP6109075B2 (ja) | 2017-04-05 |
| IL226173A (en) | 2016-10-31 |
| NZ609826A (en) | 2016-03-31 |
| JP2014514243A (ja) | 2014-06-19 |
| ZA201304840B (en) | 2014-04-30 |
| EP2646015A4 (en) | 2015-04-08 |
| EP2646015B1 (en) | 2020-04-22 |
| AU2011336692A1 (en) | 2013-05-30 |
| IL226173A0 (en) | 2013-07-31 |
| PH12013501104A1 (en) | 2013-07-08 |
| CA2817417A1 (en) | 2012-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2128160C1 (ru) | Трометаминная соль (+)-(s)-2-(3-бензоилфенил)пропионовой кислоты, способ ее получения, фармацевтическая композиция | |
| US8748482B2 (en) | Lubiprostone crystal, the use and the method for the preparation thereof | |
| JP2025114555A (ja) | 皮下注射のためのケタミン製剤 | |
| RU2600986C2 (ru) | Органические аминные соли азилсартана, способ их получения и применение | |
| US9012509B2 (en) | Method of treating non-alcoholic steatohepatitis | |
| JP4979889B2 (ja) | Ｒ型バンブテロール又はその薬学的に許容される塩の製造方法 | |
| RU2679308C2 (ru) | Активный энантиомер додецил 2-(n,n-диметиламино)-пропионата | |
| JP4959335B2 (ja) | メチルフェニデート溶液および関連する投与および製造方法 | |
| ES2516704T3 (es) | Sal ácida de tolterodina con una estabilidad eficaz para un sistema de administración transdérmica de fármacos | |
| JP6073202B2 (ja) | 静脈におけるウイルスの治療 | |
| CN101716137A (zh) | 恩替卡韦注射剂 | |
| JP2009538822A5 (enExample) | ||
| HK1198014A (en) | Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate | |
| HK1190305A (en) | Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate | |
| JP5855599B2 (ja) | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ | |
| HK1190305B (en) | Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate | |
| JP2003160489A (ja) | オンダンセトロン経皮吸収用医薬組成物 | |
| CN120172876A (zh) | 一种苯扎贝特新盐及其应用 | |
| CN103830169B (zh) | 一种盐酸法舒地尔注射液及其制备方法 | |
| BR122025008185A2 (pt) | Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo | |
| JP2016006124A (ja) | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ | |
| JPH0376302B2 (enExample) | ||
| CN1832725A (zh) | 含有三嗪的生物活性组合物 | |
| WO2005023789A1 (en) | Phosphoric acid salt of (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180109 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20181119 |